Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.
VIRAL IMMUNITY, INFECTION AND TREATMENT OF AIDS
Diss Abstr Int [B]; 48(7):1889 1988. Unique Identifier : AIDSLINE ICDB/88641189 Pontani DR; Rutgers, The State Univ. of NJ, New Brunswick, NJ
Abstract:
Two compounds, crisamicin A and amphotericin B methyl ester (AME) of known antimicrobial activity were tested as biological response modifiers and antiviral agents. Immunomodulating activity was determined in both humoral and cell-mediated systems. The induction of antibody synthesis in culture with primed spleen cells, antibody production in fully immunized mice, and the rejection of tumor allografts were used to measure the effect of each drug. The antiviral activity of these drugs was studied in animal hosts and in culture. Crisamicin A had a bimodal effect on the immune response; at high doses (greater than 1 ug/ml) the drug was immunosuppressive, while at low doses (less than 0.1 ug/ml) there was an enhancement of antibody synthesis. This was shown in both in vitro and in vivo assays. AME on the other hand significantly increased antibody production in both in vitro and in vivo systems, with no suppressive effect observed. Crisamicin A was shown to be anti-viral in herpes simplex virus infected rabbit corneas, reducing the neurological sequelae and increasing survival rates of the infected animals. AME was effective in inhibiting the infection of several enveloped viruses including herpes simplex, rabies, and influenza A. In culture experiments, the drug was shown to block the infection of H9 cells with human immunodeficiency virus when added directly, used to pretreat the target cells, or to directly neutralize the virus. AME was tested for synergism with several currently available drugs being considered for approval in the treatment of AIDS, and favorably enhanced the anti-HIV activity in culture. (Full text available from University Microfilms International, Ann Arbor, MI, as Order No: AAD87-23296)
Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*THERAPY Amphotericin B/*ANALOGS & DERIVATIVES/THERAPEUTIC USE Antibiotics/*THERAPEUTIC USE Comparative Study Human Immunocompetence/DRUG EFFECTS Naphthoquinones/*THERAPEUTIC USE THESIS
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.
